Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost 1.5% to close at $22.44 on Feb. 25. Nektar (NKTR) incurred a loss of $0.65 per share in 4Q, compared to the $0.68 loss per share estimated by analysts. Total sales generated in the quarter amounted to $23.5 million, falling short of analysts’ expectations of $30.01 million. The company’s research and development expenses were $102.7 million in the quarter, down 7% year-over-year. (See Nektar stock analysis on TipRanks) Nektar CEO Howard W.
https://www.tipranks.com/news/nektar-posts-better-than-feared-quarterly-loss-misses-on-revenues